Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $28.31 (market cap $950.14M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 3× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 59 Days on average.
| DYN | QDTE | |
|---|---|---|
Market Cap | $2.86B | $950.14M |
Volume | 3,341,579 | 170,009 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.78 | $36.60 |
52-Week Low | $14.60 | $26.85 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.29, down 0.14% with a bearish technical signal. The fund provides weekly distributions but faces criticism for yield sustainability and NAV erosion. Recent dividend payments have declined from $0.28 to $0.11, reflecting volatility compression. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
Outlook remains cautious due to structural concerns about return-of-capital distributions and underperformance in bull markets. The 24-31% yield appears unsustainable, with the fund sacrificing upside potential. Key risks include NAV decay, fee drag, and dependence on market volatility. Analyst sentiment has turned neutral to negative on the strategy's long-term viability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
